174 related articles for article (PubMed ID: 16652149)
1. Neuropeptide-stimulated cell migration in prostate cancer cells is mediated by RhoA kinase signaling and inhibited by neutral endopeptidase.
Zheng R; Iwase A; Shen R; Goodman OB; Sugimoto N; Takuwa Y; Lerner DJ; Nanus DM
Oncogene; 2006 Sep; 25(44):5942-52. PubMed ID: 16652149
[TBL] [Abstract][Full Text] [Related]
2. Neutral endopeptidase inhibits neuropeptide-mediated transactivation of the insulin-like growth factor receptor-Akt cell survival pathway.
Sumitomo M; Milowsky MI; Shen R; Navarro D; Dai J; Asano T; Hayakawa M; Nanus DM
Cancer Res; 2001 Apr; 61(8):3294-8. PubMed ID: 11309283
[TBL] [Abstract][Full Text] [Related]
3. Angiotensin II up-regulates the leukemia-associated Rho guanine nucleotide exchange factor (RhoGEF), a regulator of G protein signaling domain-containing RhoGEF, in vascular smooth muscle cells.
Ying Z; Jin L; Palmer T; Webb RC
Mol Pharmacol; 2006 Mar; 69(3):932-40. PubMed ID: 16354763
[TBL] [Abstract][Full Text] [Related]
4. Activation of p300 histone acetyltransferase activity and acetylation of the androgen receptor by bombesin in prostate cancer cells.
Gong J; Zhu J; Goodman OB; Pestell RG; Schlegel PN; Nanus DM; Shen R
Oncogene; 2006 Mar; 25(14):2011-21. PubMed ID: 16434977
[TBL] [Abstract][Full Text] [Related]
5. Bombesin stimulates invasion and migration of Isreco1 colon carcinoma cells in a Rho-dependent manner.
Saurin JC; Fallavier M; Sordat B; Gevrey JC; Chayvialle JA; Abello J
Cancer Res; 2002 Aug; 62(16):4829-35. PubMed ID: 12183443
[TBL] [Abstract][Full Text] [Related]
6. Neutral endopeptidase promotes phorbol ester-induced apoptosis in prostate cancer cells by inhibiting neuropeptide-induced protein kinase C delta degradation.
Sumitomo M; Shen R; Goldberg JS; Dai J; Navarro D; Nanus DM
Cancer Res; 2000 Dec; 60(23):6590-6. PubMed ID: 11118039
[TBL] [Abstract][Full Text] [Related]
7. Protease-activated receptor mediated RhoA signaling and cytoskeletal reorganization in LNCaP cells.
Greenberg DL; Mize GJ; Takayama TK
Biochemistry; 2003 Jan; 42(3):702-9. PubMed ID: 12534282
[TBL] [Abstract][Full Text] [Related]
8. Neutral endopeptidase inhibits prostate cancer cell migration by blocking focal adhesion kinase signaling.
Sumitomo M; Shen R; Walburg M; Dai J; Geng Y; Navarro D; Boileau G; Papandreou CN; Giancotti FG; Knudsen B; Nanus DM
J Clin Invest; 2000 Dec; 106(11):1399-407. PubMed ID: 11104793
[TBL] [Abstract][Full Text] [Related]
9. A novel role for Lsc/p115 RhoGEF and LARG in regulating RhoA activity downstream of adhesion to fibronectin.
Dubash AD; Wennerberg K; García-Mata R; Menold MM; Arthur WT; Burridge K
J Cell Sci; 2007 Nov; 120(Pt 22):3989-98. PubMed ID: 17971419
[TBL] [Abstract][Full Text] [Related]
10. Erythropoietin stimulates cancer cell migration and activates RhoA protein through a mitogen-activated protein kinase/extracellular signal-regulated kinase-dependent mechanism.
Hamadmad SN; Hohl RJ
J Pharmacol Exp Ther; 2008 Mar; 324(3):1227-33. PubMed ID: 18079357
[TBL] [Abstract][Full Text] [Related]
11. PAR1-mediated RhoA activation facilitates CCL2-induced chemotaxis in PC-3 cells.
Loberg RD; Tantivejkul K; Craig M; Neeley CK; Pienta KJ
J Cell Biochem; 2007 Aug; 101(5):1292-300. PubMed ID: 17492768
[TBL] [Abstract][Full Text] [Related]
12. RhoA mediates cyclooxygenase-2 signaling to disrupt the formation of adherens junctions and increase cell motility.
Chang YW; Marlin JW; Chance TW; Jakobi R
Cancer Res; 2006 Dec; 66(24):11700-8. PubMed ID: 17178865
[TBL] [Abstract][Full Text] [Related]
13. Gastrointestinal peptide signalling in health and disease.
Rozengurt E; Guha S; Sinnett-Smith J
Eur J Surg Suppl; 2002; (587):23-38. PubMed ID: 16144198
[TBL] [Abstract][Full Text] [Related]
14. Lentiviral vector neutral endopeptidase gene transfer suppresses prostate cancer tumor growth.
Horiguchi A; Zheng R; Goodman OB; Shen R; Guan H; Hersh LB; Nanus DM
Cancer Gene Ther; 2007 Jun; 14(6):583-9. PubMed ID: 17415380
[TBL] [Abstract][Full Text] [Related]
15. BXL-628, a vitamin D receptor agonist effective in benign prostatic hyperplasia treatment, prevents RhoA activation and inhibits RhoA/Rho kinase signaling in rat and human bladder.
Morelli A; Vignozzi L; Filippi S; Vannelli GB; Ambrosini S; Mancina R; Crescioli C; Donati S; Fibbi B; Colli E; Adorini L; Maggi M
Prostate; 2007 Feb; 67(3):234-47. PubMed ID: 17163492
[TBL] [Abstract][Full Text] [Related]
16. Galpha 12 activates Rho GTPase through tyrosine-phosphorylated leukemia-associated RhoGEF.
Suzuki N; Nakamura S; Mano H; Kozasa T
Proc Natl Acad Sci U S A; 2003 Jan; 100(2):733-8. PubMed ID: 12515866
[TBL] [Abstract][Full Text] [Related]
17. FTY720, a fungus metabolite, inhibits invasion ability of androgen-independent prostate cancer cells through inactivation of RhoA-GTPase.
Zhou C; Ling MT; Kin-Wah Lee T; Man K; Wang X; Wong YC
Cancer Lett; 2006 Feb; 233(1):36-47. PubMed ID: 16473668
[TBL] [Abstract][Full Text] [Related]
18. Modular architecture and novel protein-protein interactions regulating the RGS-containing Rho guanine nucleotide exchange factors.
Vázquez-Prado J; Basile J; Gutkind JS
Methods Enzymol; 2004; 390():259-85. PubMed ID: 15488183
[TBL] [Abstract][Full Text] [Related]
19. The vitamin D receptor agonist elocalcitol inhibits IL-8-dependent benign prostatic hyperplasia stromal cell proliferation and inflammatory response by targeting the RhoA/Rho kinase and NF-kappaB pathways.
Penna G; Fibbi B; Amuchastegui S; Corsiero E; Laverny G; Silvestrini E; Chavalmane A; Morelli A; Sarchielli E; Vannelli GB; Gacci M; Colli E; Maggi M; Adorini L
Prostate; 2009 Apr; 69(5):480-93. PubMed ID: 19107880
[TBL] [Abstract][Full Text] [Related]
20. Activated G(alpha)13 impairs cell invasiveness through p190RhoGAP-mediated inhibition of RhoA activity.
Bartolomé RA; Wright N; Molina-Ortiz I; Sánchez-Luque FJ; Teixidó J
Cancer Res; 2008 Oct; 68(20):8221-30. PubMed ID: 18922893
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
